Erenumab, sold under the brand name Aimovig, is a medication which blocks the calcitonin gene-related peptide receptor (CGRPR) for the prevention of migraine.

[3][4] Common side effects are constipation, pruritus, muscle spasms, as well as mild and mostly transient reactions at the injection site.

[9] Erenumab is a fully human monoclonal antibody blocking the calcitonin gene-related peptide receptor (CGRPR).

[13] In the United Kingdom, Erenumab was approved by the Scottish Medicines Consortium, but the National Institute for Health and Care Excellence rejected the drug on the basis that its cost-effectiveness was not sufficiently proven.

[14][15] The United States Food and Drug Administration approved the medication for the preventive treatment of migraine in adults in May 2018.